Monday, July 31, 2017 1:07:35 PM
Not so, I read your posts as well. I like your intuitions on
picking a good investment (with a little help from vidpok,
at least for me), AND your dogged stubborness in sticking
with your convictions. It's not a guarantee that it will work
out, BUT is sure did with Ariad, and I believe it will also
have similar results here (minus the drama there).
I cannot think of another biotech where the probability
for a favorable outcome is as good as AUPH. The people
running the show are top notch, have deep experience in
both the specific science (LN related issues), and the
business acumen based on a very similar (almost
the same) medical and business situation.
While it might take two years for approval, I think we'll
see upward movement before that, after all, Aurinia does
have other indications for Voc. and potential for deal-making.
Good luck to you and fellow longs,
zzaatt/amp
PS: This two year (blinded) wait seems pretty grotesque, given the
strong results in P2 and the fact that it will cost the lives
of thousands of very desperate patients. I always had a
profound contempt for the corrupt, hide-bound bureaucracy
known as the FDA and I'm hoping for big changes under Dr.Gottlieb!
Who knows, maybe some conditional approval may be possible,
it certainly should be, if the goal is to help sick people.
Recent AUPH News
- Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference • Business Wire • 05/07/2024 10:00:00 AM
- Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results • Business Wire • 05/02/2024 10:00:00 AM
- Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month • Business Wire • 05/01/2024 10:00:00 AM
- The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program • Business Wire • 04/30/2024 10:00:00 AM
- New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference • Business Wire • 04/16/2024 02:48:00 PM
- Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024 • Business Wire • 04/15/2024 10:00:00 AM
- Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference • Business Wire • 04/09/2024 10:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:44:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:43:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:42:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:41:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:10:10 PM
- Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program • Business Wire • 02/29/2024 01:30:00 PM
- Aurinia to Participate in Upcoming Investor Healthcare Conferences • Business Wire • 02/27/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:35:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:33:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:31:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:29:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:27:55 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 02/22/2024 09:19:43 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/15/2024 11:16:17 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 11:06:50 AM
- Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value • Business Wire • 02/15/2024 11:00:00 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:27:55 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM